Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus
Objective Antiphospholipid syndrome (APS) is characterised by increased cardiovascular morbidity and mortality, related to thrombo-inflammatory and atherogenic mechanisms. We examined the achievement of traditional cardiovascular risk factor (CVRF) therapeutic goals in APS versus other high cardiova...
Saved in:
Main Authors: | Eleana Bolla, Nikolas Tentolouris |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-04-01
|
Series: | Lupus Science and Medicine |
Online Access: | https://lupus.bmj.com/content/8/1/e000579.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Coexistence of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Sjogren Syndrome, Antiphospholipid Syndrome, and Ankylosing Spondylitis
by: Moshiur Rahman Khasru, et al.
Published: (2021-01-01) -
Cardiovascular Risk Factors in the Antiphospholipid Syndrome
by: Felipe Freire da Silva, et al.
Published: (2014-01-01) -
Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis
by: Luis Rodríguez-Rodríguez, et al.
Published: (2012-01-01) -
Causal association between diabetes mellitus and rheumatoid arthritis: A bidirectional Mendelian randomization study
by: Zhirong Gu, et al.
Published: (2024-09-01) -
Catastrophic Antiphospholipid Syndrome
by: Rawhya R. El-Shereef, et al.
Published: (2016-01-01)